Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Neuro Oncol. 2022 Jun 1;24(6):997-1007. doi: 10.1093/neuonc/noab274.
Neuro Oncol. 2022.
PMID: 34850167
Free PMC article.
Clinical Trial.